CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Antiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)
Updated · Methodology
Mechanism
Darunavir is taken only with a booster (ritonavir or cobicistat), and the boosted regimen slows the clearance of drugs that depend heavily on CYP3A, so their blood levels rise (darunavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Cisapride is one of these drugs: at high levels it can cause serious or even life-threatening effects (darunavir SmPC, EMA). The documents give no study data with figures for this pair. Higher cisapride levels raise the risk of serious arrhythmias (ritonavir SmPC, EMA). The SmPC of clarithromycin, another CYP3A4 inhibitor, reports that raised cisapride levels can prolong the QT interval and cause ventricular arrhythmias (clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
The danger of the pair is serious heart rhythm disorders (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). These include QT prolongation, ventricular tachycardia, ventricular fibrillation and torsade de pointes (clarithromycin SmPC on its combination with cisapride, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting, and a sustained episode can turn into ventricular fibrillation and cardiac arrest.
Management
The combination is contraindicated. Cisapride is on the contraindication list of darunavir boosted with either ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA). When ritonavir is the booster, the ritonavir documents also contraindicate cisapride (ritonavir SmPC, EMA, and ritonavir label, US Food and Drug Administration, FDA). The US darunavir label refers to the ritonavir contraindications (darunavir FDA label). Cisapride is not in the Spanish medicines register CIMA, so the level of risk comes from the darunavir and ritonavir documents. If a patient takes cisapride obtained in another country, do not prescribe darunavir with it (darunavir SmPC, EMA). Before starting darunavir, review all current medicines and read the prescribing information of each of them and of the booster, whether ritonavir or cobicistat (darunavir SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Claritromicina, Klacid 500 mg (nº registro 60515) (2024)– AEMPS, CIMA, nº registro 60515 (Klacid 500 mg comprimidos recubiertos con película), revisión 10/2024, secciones 4.3, 4.4 y 4.5
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3